Search results
12 gru 2022 · Hereditary hemorrhagic telangiectasia (HHT), formerly Osler-Weber-Rendu, is an inherited (autosomal dominant) disease that results in malformed blood vessels (see Image. Telangiectasia on the Tongue).
The Rendu-Osler-Weber syndrome or Hereditary Hemorrhagic Telangiectasia is a rare systemic fibrovascular dysplasia which bears, as basic defect, an alteration in the elastic and muscle layers of vessel walls, making them more vulnerable to spontaneous ruptures and injuries 1, 2. The disease is autosomal dominant, although in about 20% of the ...
4 maj 2011 · [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. Acta Otorrinolaringol Esp 2007; 58: 129–132.
1 gru 2023 · We identified 103 articles describing oral and dental considerations of patients with HHT, primarily case reports. Most reported oral telangiectasias of the tongue, lips, and palate. Many reported management of bleeding and the use or recommendation of prophylactic antibiotics before dental procedures.
26 cze 2000 · Treatment of manifestations: Nosebleeds are treated with humidification, topical moisturizing therapy, hemostatic products, antifibrinolytic therapy, ablation therapy, systemic antiangiogenic agents, septodermoplasty, and nasal closure as needed.
7 sty 2020 · Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, no mechanism-based targeted therapy is available so far. In this review, we will focus on the development of new drugs aiming at correcting the altered signaling pathways in HHT patients.
18 lut 2021 · This progress is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding.
